



BSW Formulary Updates and Recent Decisions – March 2025

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- [Tocilizumab \(x 4 doses\) to treat the cytokine release syndrome for patients on CAR-T or bispecific antigen therapy \(NHSE Commissioned\)](#) – added to formulary with RED TL, requires completion of a Blueteq form.
- [Liposomal Amikacin for the treatment of non-tuberculous mycobacterial \(NTM\) lung infections caused by Mycobacterium avium Complex \(MAC\) in adults with limited treatment options who do not have cystic fibrosis \(NHSE Commissioned\)](#) – added to formulary with RED TL Patients will be reviewed at 6 months before continued treatment.
- [Buvidal \(long-acting buprenorphine injection\)](#) – added to formulary in-line with current practice. RED TL in Wiltshire. BaNES GPs continue to prescribe, where necessary, until patients have been reviewed by Turning Point when they take over the service in April 2025.
- [Naloxone – “Take home” formulations](#) added to formulary with RED TL in-line with current practice. All formulations being prescribed by specialist drug addiction services.

New and Updated Prescribing Guidelines and Shared Care Agreements

- [NEW Cinacalcet SCA](#) - used to treat patients with primary hyperparathyroidism who are not fit for surgery.
- [UPDATE Self-Monitoring of Blood Glucose in Diabetes Guidance \(SMBG\)](#) – updated to remove non formulary medications and discontinued free of charge devices. Updated guidance from DVLA.
- [UPDATE Oral Semaglutide Guidance](#) – updated to remove out of stock information.

Minor amendments to Netformulary

- Suprecor and Promixin discontinued and moved to non-formulary
- Buccolam SCA feedback received from a nurse saying she has had trouble with schools that Think there should be a sealed cap for them to use this in emergency situations. Wording has been added to the SCA to state that the product is not manufactured like this which the nurses can use to signpost schools/caring organisations to.
- link in relevant formulary section to distribution arrangements during PERT shortages.
- Ogluo removed from formulary (was added temporarily) as Glucogen is back in stock.
- Fobumix has a new license for AIR use.
- Somatropin shared care removed and is now amber only. To be replaced with guidance, to follow.

What the BSW ICB formulary team are currently working on

- Reviewing Cequa, a cost effective brand of cyclosporin eye drops
- ADHD guidance on combination treatment
- Updating the APC Terms of Reference
- Updating the dronedarone SCA
- Vitamin D guidance update
- Amiodarone SCA being considered

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles



Bath and North East Somerset,
Swindon and Wiltshire Together

are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net